

30th ANNUAL REPORT 2015 - 2016



COMBAT DRUGS LIMITED

Regd Office: 9-109/9, Plot No. 112, Road No. 14, Gayatri Nagar,
Boduppal, R.R. Dist. - 500 039. Telangana, India.
www.combatdrugs.in Email: investorinfo@combatdrugs.in

30th ANNUAL GENERAL MEETING

Date : 29-09-2016
Day : Thursday
Time : 11.00 AM
Venue : 9-109/9, Plot No: 112, Rd. No.14,
Gayatri Nagar, Bouduppall,
R.R.District-500039,
Telangana, INDIA

CONTENTS

| | |
|---|----|
| Notice | 03 |
| E-voting instructions | 07 |
| Director's Report | 11 |
| Management Discussion and Analysis | 19 |
| Report on Corporate Governance | 22 |
| Corporate Governance Report - Auditor Certificate | 37 |
| CEO and CFO Certification | 38 |
| Secretarial Audit Report | 40 |
| Auditor's Report | 48 |
| Financial - Balance Sheet | 55 |
| Profit and Loss Account | 56 |
| Notes on Accounts | 57 |
| Cash Flow Statement | 63 |
| Consent Letter | 64 |
| Attendance slip / Proxy form | 65 |
| Polling papers | 66 |

No Gifts will be distributed at the meeting.

COMBAT DRUGS LIMITED

CIN NO: CL23230TG1986PLC006781

BOARD OF DIRECTORS

Shri SUCHIT MOHAN LAL

Managing Director

Shri SUSHANT MOHAN LAL

Director

Shri BHUPENDRALAL WAGHRAY

Chairman & Independent Director

Smt VEMURI SHILPA

Independent Woman Director

Auditors:

Anandam & Company
Chartered Accountants
Secunderabad.
TELANGANA, India

Registered & Corporate Office:

9-109/9, Plot No.112, Rd.No.14,
Gayatri Nagar, Boduppall,
R.R.District-500039
TELANGANA, India

Bankers:

Karnataka Bank Limited
RaJ Bhavan Road.
HYDERABAD
TELANGANA, India

AP Mahesh Co-operative Bank Ltd
M.G.Road
Secunderabad
TELANGANA, India

Legal Advisors:

N. Rajeshkar Reddy, Advocates
204,2nd Floor, HilinePratap Apartments, Kachiguda 'X' Road, Hyd.

REGISTRARS & TRANSFER AGENTS:

M/s VENTURE CAPITAL &

CORPORATE SERVICES PRIVATE LIMITED

12-10-167, BHARAT NAGAR, HYDERABAD-500 018,
TELANGANA Phone: (+91)-4023818475/476 FAX: 23868024
Email id: info@vccipl.com

NOTICE

Notice is hereby given that the Thirtieth Annual General Meeting of the members of Combat Drugs Limited will be held on Thursday, the 29th day of September, 2016 at 11:00 A.M. at the Registered Office of the Company at 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Boduppal, R.R.District-500039, Telangana, INDIA to transact the following items of business:

ORDINARY BUSINESS:

1. ADOPTION OF AUDITED ACCOUNTS AND REPORTS

To receive, consider and adopt the Balance Sheet as at 31st March, 2016, the Profit and Loss Account for the year ended as on that date, Directors' Report and Auditors' Report thereon.

2. RE-APPOINTMENT OF DIRECTOR

To appoint a Director in place of Smt. Vemuri Shilpa, Independent Director, who retires by rotation and being eligible offers herself for re-appointment.

3. APPOINTMENT OF AUDITORS

To consider and if thought fit to pass the following resolution with or without modification(s) as an Ordinary Resolution:

“RESOLVED THAT M/s Anandam & Company, Chartered Accountants, be and are hereby appointed as Auditors of the Company to hold the office from the conclusion of this Annual General Meeting of the Company until the conclusion of the next Annual General Meeting of the Company at a remuneration to be fixed by the Board of Directors in consultation with the Auditors.”

SPECIAL BUSINESS

4. To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT Mr. Bhupendralal Waghray, who was appointed as an Independent Director of the Company and who holds office up to the date of this Annual General Meeting and in respect of whom a notice has been received from a member of the Company in terms of Section 161 of the Companies Act, 2013, be and is hereby appointed as a Director of the Company liable to retire by rotation.”

By the Order of the Board
For **COMBAT DRUGS LIMITED**

Sd/-

SUCHIT MOHAN LAL
MANAGING DIRECTOR

Place: Hyderabad
Date: 25.08.2016

NOTES:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND SUCH PROXY NEED NOT BE A MEMBER OF THE COMPANY. THE PROXIES TO BE EFFECTIVE SHOULD BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LATER THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.
2. Register of members and share transfer books of the company will remain closed from 23/09/2016 to 29/09/2016 (both days inclusive).
3. Members/Proxies should bring the attendance slips duly filled in and signed for attending the meeting.
4. Members, who are holding shares in the identical order of names in more than one folio, are requested to write to the Company to enable it to consolidate their holding in one folio.
5. As per the provisions of the Companies Act, 2013, facility for making nomination is available for Members of the Company in respect of shares held by them. The members, who wish to nominate a person, may furnish the required details to the Company in prescribed form.
6. The Ministry of Corporate Affairs has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the companies and has issued circulars stating that service of notice/ documents including Annual Report can be sent by e-mail to its members. To support this green initiative of the Government in full measure, members who have not registered their e-mail addresses, so far, are requested to register their e-mail addresses. In respect of electronic holdings, with the Depository through their concerned Depository Participants and members who hold shares in physical form are requested to register the same with our RTA, M/S Venture Capital & Corporate Services Private Limited, 12- 10-167, Bharat Nagar, Hyderabad-500 018, Telangana.
7. Electronic copy of the Notice of the 30th Annual General Meeting of the Company inter alia indicating the process and manner of E-voting along with Attendance Slip and Proxy Form is being sent to all the members whose email Ids are registered with the Company/Depository Participant(s) for communication purposes unless any Member has requested for a hard copy of the same. For Members who have not registered their Email address, physical copies of the Notice of the 30th Annual General Meeting of the Company inter alia indicating the process and manner of E-voting along with Attendance Slip and Proxy Form is being sent in the permitted mode. Members may also note that the Notice of the 30th Annual General Meeting and the Annual Report for 2015-16 will also be available on the Company's website www.combatdrugs.in for their download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office in Hyderabad for inspection between 2:00 p.m. to 4:00 p.m. on all working days from Monday to Friday. Even after registering for E-communication, Members are entitled to receive such communication in physical form, upon making a request for the same, by post,

free of cost. For any communication, the Members may also send requests to the Company or to its Registrar and Share Transfer Agent, at the following Email ID: info@vccipl.com / investorinfo@combatdrugs.in

8. VOTING THROUGH ELECTRONIC MEANS

In compliance with provisions of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 and regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations), the company is pleased to provide members facility to exercise their votes for all the resolutions detailed in the Notice of the 30th Annual Report of the company and the business may be transacted through e-voting. The company has engaged the services of National Depository Services Limited (NDSL) as the authorized agency to provide the e-voting facility.

The detailed instructions for E-voting are given as a separate attachment to this Notice.

9. Members are requested to quote their Registered Folio No. on all correspondence(s) with the Company.

Mr. S. S. Marthi (Membership No.FCS 1989), Practicing Company Secretary, is appointed as scrutinizer to conduct E-voting.

By the Order of the Board
For **COMBAT DRUGS LIMITED**

Sd/-

SUCHIT MOHAN LAL
MANAGING DIRECTOR

Place: Hyderabad
Date: 25.08.2016

E-VOTING

- I. In compliance with provisions of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 and regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations), the Company is pleased to provide members facility to exercise their right to vote on resolutions proposed to be considered at the Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting Services. The facility of casting the votes by the members using an electronic voting system from a place other than venue of the AGM ("remote e-voting") will be provided by National Securities Depository Limited (NSDL).
- II. The facility for voting through ballot paper shall be made available at the AGM and the members attending the meeting who have not cast their vote by remote e-voting shall be able to exercise their right at the meeting through ballot paper.
- III. The members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.
- IV. The remote e-voting period commences on 26th September, 2016 (9:00 am) and ends on 28th September, 2016 (5:00 pm). During this period members' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of 23rd September, 2016 (cut off date), may cast their vote by remote e-voting. The remote e-voting module shall be disabled by NSDL for voting thereafter. Once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently.
- V. The process and manner for remote e-voting are as under:
 - A. In case a Member receives an email from NSDL [for members whose email IDs are registered with the Company/Depository Participants(s)] :
 - (i) Open email and open PDF file viz; "remote e-voting.pdf" with your Client ID or Folio No. as password. The said PDF file contains your user ID and password/PIN for remote e-voting. Please note that the password is an initial password.
 - (ii) Launch internet browser by typing the following URL: <https://www.evoting.nsdl.com/>
 - (iii) Click on Shareholder - Login
 - (iv) Put user ID and password as initial password/PIN noted in step (i) above. Click Login.
 - (v) Password change menu appears. Change the password/PIN with new password of your choice with minimum 8 digits/characters or combination thereof. Note new password. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

- (vi) Home page of remote e-voting opens. Click on remote e-voting: Active Voting Cycles.
 - (vii) Select "EVEN" of "Combat Drugs Limited".
 - (viii) Now you are ready for remote e-voting as Cast Vote page opens.
 - (ix) Cast your vote by selecting appropriate option and click on "Submit" and also "Confirm" when prompted.
 - (x) Upon confirmation, the message "Vote cast successfully" will be displayed.
 - (xi) Once you have voted on the resolution, you will not be allowed to modify your vote.
 - (xii) Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer through e-mail to spcsp1@gmail.com with a copy marked to evoting@nsdl.co.in
- B. In case a Member receives physical copy of the Notice of AGM) [for members whose email IDs are not registered with the Company/Depository Participants(s) or requesting physical copy] :
- (i) Initial password is pasted as below/at the bottom of the Attendance Slip / behind cover page for the AGM

| | | |
|-------------------------------------|---------|-----------------------|
| EVEN (Remote e-voting Event Number) | USER ID | PASSWORD/PIN |
| 104983 | | Refer Sticker in Book |
 - (ii) Please follow all steps from Sl. No. (ii) to Sl. No. (xii) above, to cast vote.
- VI. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Members and remote e-voting user manual for Members available at the downloads section of www.evoting.nsdl.com or call on toll free no.: 1800-222-990.
 - VII. If you are already registered with NSDL for remote e-voting then you can use your existing user ID and password/PIN for casting your vote.
 - VIII. You can also update your mobile number and e-mail id in the user profile details of the folio which may be used for sending future communication(s).
 - IX. The voting rights of members shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date of 24th September, 2016.
 - X. Any person, who acquires shares of the Company and become member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e. 26th August, 2016, may obtain the login ID and password by sending a request at evoting@nsdl.co.in or Issuer/RTA.

However, if you are already registered with NSDL for remote e-voting then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password by using "Forgot User Details/ Password" option available on www.evoting.nsdl.com or contact NSDL at the following toll free no.: 1800-222-990.

- XI. A member may participate in the AGM even after exercising his right to vote through remote e-voting but shall not be allowed to vote again at the AGM).
- XII. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting as well as voting at the AGM through ballot paper.
- XIII. Mr. S.S. Marthi, Company Secretary (Membership No. FCS 1989) has been appointed as the Scrutinizer for providing facility to the members of the Company to scrutinize the voting and remote e-voting process in a fair and transparent manner.
- XIV. The Chairman shall, at the AGM), at the end of discussion on the resolutions on which voting is to be held, allow voting with the assistance of scrutinizer, by use of "Ballot Paper" for all those members who are present at the AGM but have not cast their votes by availing the remote e-voting facility.
- XV. The Scrutinizer shall after the conclusion of voting at the general meeting, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than three days of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favor or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- XVI. The Results declared along with the report of the Scrutinizer shall be placed on the website of the Company www.combatdrugs.in and on the website of NSDL immediately after the declaration of result by the Chairman or a person authorized by him in writing. The results shall also be immediately forwarded to the BSE Limited, Mumbai.

Pursuant to Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the brief profile of Directors eligible for re-appointment.

- i. Name of Director : Mr. BHUPENDRALAL WAGHRAY
DIN : 07337149
Date of Birth : 01/08/1955
Date of Appointment : 14/11/2015
Qualification : BSc
Other Directorship : NIL
Expertise : Finance
Chairman/Members of the Committee in other Companies : NIL
No of shares held in the Company : NIL
- ii. Name of Director : Mrs. VEMURI SHILPA
DIN : 07140155
Date of Birth : 28/12/1978
Date of Appointment : 30/03/2015
Qualification : MBA
Other Directorship : NIL
Expertise : H.R
Chairman/Members of the Committee in other Companies: NIL
No of shares held in the Company : NIL

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013.

ITEM NO. 4

Mr. BHUPENDRALAL WAGHRAY was appointed as an Independent Director of the Company pursuant to Section 161 of the Companies Act, 2013, effective from 14th November, 2015 and holds office as director only upto the date of ensuing AGM. The Company has received a notice from a member in terms of Section 160 of the Companies Act, 2013 proposing the candidature of Mr. BHUPENDRALAL WAGHRAY as an Independent Director of the Company liable to retire by rotation along with prescribed deposit of Rs.1,00,000/-.

Save and except Mr. BHUPENDRALAL WAGHRAY none of the other Directors and their relatives are in any way, are concerned or interested, financially or otherwise, in the resolution set out in Item No. 4. Mr. BHUPENDRALAL WAGHRAY is not disqualified from being appointed as an Independent Director in terms of Section 164 of the Act and has given his consent to be appointed as a Director.

The Board recommends the appointment of Mr. BHUPENDRALAL WAGHRAY as Independent Director liable to retire by rotation and propose to pass the resolution set out in Item No. 4 of the notice as an Ordinary Resolution.

By the Order of the Board
For **COMBAT DRUGS LIMITED**

Place: Hyderabad
Date: 25.08.2016

Sd/-
SUCHIT MOHAN LAL
MANAGING DIRECTOR

DIRECTORS' REPORT

Dear Members,

Your Directors have pleasure in submitting before you the Thirtieth Annual Report of the Company together with the Audited Statements of Accounts for the financial year ended 31st March, 2016.

1. FINANCIAL RESULTS

The Company's financials for the year under review along with the corresponding figures of the previous year's figures are as under:-

(Amount in Lakhs)

| | For the year ended | |
|---|--------------------|------------|
| | 31-03-2016 | 31-03-2015 |
| Net Sales /Income from Business Operations | 22.30 | 9.63 |
| Other Income | 0.54 | 8.77 |
| Total Income | 22.84 | 18.40 |
| Less Interest | 0.00 | 0.00 |
| Profit before Depreciation | (119.22) | (345.18) |
| Less Depreciation | 8.56 | 23.21 |
| Profit after depreciation and Interest | (127.78) | (368.39) |
| Less Current Income Tax | 0.00 | 0.00 |
| Less Previous year adjustment of Income Tax, | 0.00 | 0.00 |
| Less Deferred Tax | 0.00 | 0.00 |
| Net Profit after Tax | (127.78) | (368.39) |
| Dividend (including Interim if any and final) | 0.00 | 0.00 |
| Net Profit after dividend and Tax | (127.78) | (368.39) |
| Amount transferred to General Reserve | 0.00 | 0.00 |
| Balance carried to Balance Sheet | (127.78) | (368.39) |
| Earning per share (Basic) | (1.60) | (4.60) |
| Earning per Share (Diluted) | (1.60) | (4.60) |

2. DIVIDEND

As the company did not earn distributable profits, the board of directors did not recommend any dividend for the financial year under review. Since the company has not declared any dividend for more than 10 years. The provisions of Section 125 (2) of the Companies Act, 2013 do not apply.

3. RESERVES

The Board did not propose to transfer any amount to reserves.

4. REVIEW OF BUSINESS OPERATIONS AND FUTURE PROSPECTS

During the year under review, your company achieved a turnover of Rs.22.30 Lakhs in the year 2015-16 as compared to Rs. 9.63 Lakhs during 2014-2015

growing at more than 100%. The Company is getting their Branded Formulations of WHO GMP standards manufactured on Third Party manufacturing basis with a reputed company in Hyderabad. The company is very confident of building very decent business volumes in due course of time.

5. CHANGE IN THE BUSINESS OF THE COMPANY:

During the year under review, the company did not change its line of activity.

6. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management's Discussion and Analysis Report for the year under review, as stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is presented in a separate section forming part of the Annual Report – Annexure A.

7. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION

Your Company has taken adequate steps to adhere to all the stipulations laid down under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. A report on Corporate Governance is included as part of this Annual Report as "Annexure – B".

Certificate from the Statutory Auditors of the company M/s. Anandam & Co, Chartered Accountants confirming the compliance with the conditions of Corporate Governance as Stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is included as part of this report as "Annexure C"

8. LISTING & TRADING ON STOCK EXCHANGES

The Equity Shares of the Company are listed on The Bombay Stock Exchange Limited, Mumbai. The Market price of the Share as on 31st March, 2016 was Rs.6.06 per share. The Company confirms that it has paid the Annual Listing Fee for the year 2016-17 to BSE. Your Directors are pleased to inform you that the Suspension in trading in the securities of the company "for surveillance measures" was revoked by BSE and the trading resumed in the Equity Shares of the Company with effect from 27th January 2016 with a price of Rs.6.63 per equity share.

9. DEMATERIALISATION OF SHARES

82.64% of the company's paid up Equity Share Capital is in dematerialized form as on 31st March, 2016 and balance 17.37% is in physical form. The Company's Registrars are M/s Venture Capital & Corporate Services Private Limited, 12-10-167, Bharat Nagar, Hyderabad-500 018, Telangana. Phone: (+91)-4023818475/476 FAX: +91 40 23868024 Email id: info@vccipl.com.

10. BOARD EVALUATION

The Board of Directors has carried out an annual evaluation of its own performance, Board committees and individual directors pursuant to the provisions of the Act and the corporate governance requirements as prescribed by SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 ("SEBI Listing Regulations").

The performance of the Board was evaluated by the Board after seeking inputs from all the directors on the basis of the criteria such as the Board composition and structure, effectiveness of board processes, information and functioning, etc.

The Board and the Nomination and Remuneration Committee ("NRC") reviewed the performance of the individual directors on the basis of the criteria such as the contribution of the individual director to the Board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc. In addition, the Chairman was also evaluated on the key aspects of his role.

In a separate meeting of independent Directors, performance of non independent directors, performance of the board as a whole and performance of the Chairman was evaluated, taking into account the views of executive directors and non-executive directors. The same was discussed in the board meeting that followed the meeting of the independent Directors, at which the performance of the Board, its committees and individual directors was also discussed.

11. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

No material changes and commitments affecting the financial position of the Company occurred between the end of the financial year to which this financial statements relate and the date of this report.

12. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE

There is no order passed by any Court or Tribunal or forum which impacted or is likely to impact the "Going concern status" of the company.

13. DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS.

The company has adequate internal financial controls and has a separate Audit committee to assess the internal controls and guide the company accordingly.

14. DETAILS OF SUBSIDIARIES, JOINT VENTURES, ASSOCIATE COMPANIES & THEIR PERFORMANCE

The Company does not have any subsidiary or joint venture or associate company.

15. DEPOSITS

The Company has neither given nor accepted any Public Deposits during the year under review.

16. STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY

The Company does not have any Risk Management Policy as the elements of risk threatening the Company's existence are very minimal.

17. DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY INITIATIVES

The provisions of Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility does not apply to the company.

18. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013

There were no loans, guarantees or investments made by the Company under Section 186 of the Companies Act, 2013 during the year under review and hence the said provision is not applicable.

19. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES

The related party transactions entered into by the company during the financial year under review have been disclosed vide Note No. 20 (iv) of the financial statements of the company for the financial year ended 31st March 2016. All the transactions entered into are at an arm's length basis and in the ordinary course of business. The relevant details in form AOC-2 is enclosed hereto at Annexure –B to Corporate Governance.

20. DIRECTORS RESPONSIBILITY STATEMENT

In accordance with the provisions of Section 134(5) of the Companies Act, 2013 the Board hereby submit its responsibility Statement:—

(a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) The Directors had prepared the annual accounts on a going concern basis; and

(e) The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.

(f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

21. EXPLANATION OR COMMENTS ON QUALIFICATIONS, RESERVATIONS OR ADVERSE REMARKS OR DISCLAIMERS MADE BY THE AUDITORS AND THE PRACTICING COMPANY SECRETARY IN THEIR REPORTS

There were no qualifications, reservations or adverse remarks made by either the Auditors or by the Practicing Company Secretary in their respective reports except the Disclaimers of Professional Tax Payment in Auditor Report & Secretarial Audit Report and on Company's Manufacturing Licence Under Renewal in secretarial Audit Report.

The Company has subsequently initiated the process of payment of Professional Tax. The company has a valid Drug Manufacturing and Wholesale Licence and has applied for the Renewal of the Drug Manufacturing Licence which is a continuous process.

22. SHARE CAPITAL

The Equity Share Capital of the Company is 8,000,000 Shares of Rs.10/- each. The Company has not bought back any of its securities nor has it issued any Equity or Sweat Equity or bonus Shares or has not provided any Stock Option Scheme to the employees during the year under review. There is no Change in Promoter Holding during the Financial year.

23. COMPANY'S POLICY RELATING TO DIRECTORS APPOINTMENT, PAYMENT OF REMUNERATION AND DISCHARGE OF THEIR DUTIES

The Nomination & Remuneration Committee is vested with the powers to recommend the Appointment of a Director and fix, recommend the Remuneration accordingly.

Managerial Remuneration:

A) Details of the ratio of the remuneration of each director to the median employee's remuneration and other details as required pursuant to Rule 5 (1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are as under:

| Name | Designation | Yearly Remuneration (Rs). |
|----------------------------|----------------------|----------------------------------|
| 1. Mr.Suchit Mohan Lal | Managing Director | 2,40,000.00. |
| 2. Mr.Sushant Mohan Lal | Executive Director | 2,40,000.00 |
| 3. Shri B.N.Gnana Prakash. | Independent Director | NIL |
| 4. Smt. Vemuri Shilpa | Independent Director | NIL |
| 5. Mr. Bhupendralal Waghay | Independent Director | NIL |

The Remuneration of Mr.Suchit Mohan Lal, Managing Director was increased and approved by the Shareholders in the last AGM. However, Mr. Suchit Mohan Lal had requested that he will be drawing the enhanced Remuneration from the next financial year, ie 1st April 2016 in view of the financial crunch in the company. The request was accepted by the Board of Directors and a resolution was passed to this effect.

B) Details of every employee of the Company as required pursuant to 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 :

1. The Ratio as such is not applicable.

C) Any director who is in receipt of any commission from the company and who is a Managing Director or Whole-time Director of the Company shall receive any remuneration or commission from any Holding Company or Subsidiary Company of such Company subject to its disclosure by the Company in the Board's Report — NIL

24. ANNUAL RETURN

The extracts of the Annual Return pursuant to the provisions of Section 92 read with Rule 12 of the Companies (Management and administration) Rules, 2014 in Form MGT 9 is attached to this Report at Annexure 'F'.

25. BOARD MEETINGS

The Board during the financial year 2015-16 met Seven times. Detailed information regarding the meetings of the Board are included in the report on Corporate Governance, which forms part of the Board's Report.

The Company constituted 3 Committees as under:

- (I) Audit Committee;
- (II) Nomination & Remuneration Committee ;
- (III) Share holders Grievance Relationship/Share Transfer Committee

The details are given as Annexure 'B' in the Corporate Governance Report.

26. DIRECTORS

In accordance with the provisions of the Companies Act, 2013, Sri Bhupendralal Waghray, was appointed as an Independent Director on 14-11-2015. Shri B.N.Gnana Prakash. Independent Director resigned from the Company as an Independent Director with effect from 14-11-2015 due to his pre-occupation and his resignation was accepted by the Board.

Shri Bhupendralal Waghray Director of the Company and Vemuri Shilpa, Director of the Company are liable to retire by rotation at the ensuing Annual General Meeting and being eligible, offer themselves for re-appointment.

27. DECLARATION OF INDEPENDENT DIRECTORS

The Independent Directors have submitted declarations disclosing to the Board that they fulfill the criteria stipulated under Section 149(6) of the Companies Act, 2013 so as to qualify themselves to be appointed as Independent Directors under the provisions of the Companies Act, 2013 and the relevant rules made there under.

28. DISCLOSURE OF COMPOSITION OF AUDIT COMMITTEE AND PROVIDING VIGIL MECHANISM

The Audit Committee consists of the following members:

- i) Shri Bhupendralal Waghray ii) Smt Vemuri Shilpa
- iii) Shri. Sushant Mohan Lal

The above composition of the Audit Committee consists of independent Directors viz., Shri Bhupendralal Waghray and Smt Vemuri Shilpa, who form the majority. The Audit committee was reconstituted on 14th November, 2015 after the resignation of Shri B.N. Gnana Prakash and co-option of Shri Bhupendralal Waghray, as Independent Director of the Company. The Audit Committee reports to the Board. The Company has a vigil mechanism in place.

29. CORPORATE SOCIAL RESPONSIBILITY:

The provisions of the Companies Act, 2013 and rules made there under (“the Act”), forming of a Corporate Social Responsibility (CSR) Committee is Not Applicable to the Company.

30. PARTICULARS OF EMPLOYEES:

Information as required under the provisions of Rules 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is given elsewhere in the report. As per the provision to Rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the particulars of employees posted and working outside India is - NIL.

31. Details of Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outflow [Clause (m) of sub-section (3) of section 134 of the Act, r/w Rule 8 of the Companies (Accounts) Rules, 2014]

(A) Conservation of energy

The Company is getting their Products manufactured on Third Party Manufacturing basis & hence the energy consumed for manufacturing activities during the year was NIL & hence, No Additional Investments or proposals were implemented for reduction of consumption of energy.

(B) Technology absorption: The Company did not carry out any R & D during the year under review.

(C) Foreign exchange earnings and Outgo: NIL

32. ACKNOWLEDGEMENTS

Your Directors place on record their sincere thanks to Bankers, Business Associates, Consultants, and various Government Authorities for their continued support extended to your Companies activities during the year under review. Your Directors also acknowledge gratefully the shareholders for their support and confidence reposed on your Company.

For and on behalf of the Board
For COMBAT DRUGS LIMITED

Place: Hyderabad
Date: 25.08.2016

Sd/-
SUCHIT MOHANLAL
MANAGING DIRECTOR

Sd/-
SUSHANT MOHANLAL
DIRECTOR

MANAGEMENT DISCUSSION & ANALYSIS

A. Global Pharmaceutical Industry

The global pharmaceutical market grew steadily from \$887 billion in 2010 to approximately \$1.07 trillion in 2015 amidst a global volatile economic scenario. The positive factors such as, the effect of aging populations, increase of chronic/lifestyle related diseases, introduction of new specialty medicines, increased accessibility of patients to medical infrastructure, expansion of emerging markets and advances in treatment and allied technologies were mainly responsible for the growth of the global pharmaceutical market. If this growth continues, the Global spending on medicines is expected to reach \$1.4 trillion by 2020.

- (i) **Global Generic Pharma:** Generic drugs increase the accessibility and affordability of modern day pharmaceutical products. It allows access to expensive treatments at much lower cost. It is expected that the global market for generics would increase to \$518 billion in 2018 as compared to \$269 billion in 2012. The industry has been growing at 8.4% and in terms of global generics, it is expected that the economies are all set to grow at a rate of 15-20% over the next few years, leading them to form an important share in the overall pharmaceutical generic industry.

(B) Indian Pharmaceutical Industry

Approximately 2.4% of the total global market share in terms of value and 10% in terms of volume is held by the Indian pharmaceutical Industry. It is currently the sixth largest Pharma market in the world in terms of size with a Compounded Annual Growth Rate (CAGR) of 17.46% to become a USD 20 billion industry, as on January 2016. It is projected to grow by 15.92% by FY2020.

About 70% of the total revenue collected by the Indian pharmaceutical industry is generated by generic drugs, followed by OTC medicines, which generates 21% of the total revenue. The remaining 9% is occupied by patented drug sales. About 20% of the global generic orders are supplied by the Indian Pharma sector. This makes the country, world's largest generic medicine provider.

i) Opportunities for the pharmaceutical sector

Growing demand for healthcare programs: With the rising demand for several healthcare programs, the growth in Formulation medicine sale is expected in the coming years.

Rise in lifestyle oriented diseases: The lifestyle of people have gone through drastic changes through recent years. This has led to an increase in chronic diseases, giving rise to increase in usage of medicines.

Growth in senior population: The population of elderly people is increasing in the country which is an opportunity for the Pharma industry to grow as the possibility of chronic diseases among the senior population is higher, which will invariably result in intake of more drugs and medicines.

Patent expiries: In the year 2016, a huge portion of patent drugs, are going to expire worldwide. As a result, the Indian Pharma companies shall get rights of manufacturing drug formulations. which opens up a huge market for the Indian Pharmaceutical industry.

ii) Challenges and Threats for the pharmaceutical sector

Pricing pressure: It is expected that in the coming years, generic players might witness decline in their margins because of increasing competition.

Higher competition: There are many companies around the globe engaged in the manufacturing of generic drugs. The competition is growing at a faster rate. It may be a challenge as far as the profit margin of your company is concerned.

Working Capital Requirements: The Company is not enjoying any limits from any Banks & is in the process of obtaining Working Capital limits from Banks.

iii) PRODUCT WISE PERFORMANCE:

The Company is operating in only one segment of Pharmaceutical Formulations Marketing of Tablets, Liquids & Capsule Fixed dosage forms.

The Company has drawn up a strategy to get its products manufactured in various locations & will position itself as a low-cost manufacturer of various high class Finished dosage forms and therapeutic products. The company is drawing up different strategies for Marketing the Products locally.

iv) COMPANY'S OUTLOOK & CONCERNS:

The Company has decided to Switch over from Prescription (Rx) to OTC as it would prove to be a growth driver due to low cost of these drugs, growing aged population and encouragement by the Government schemes like Jan Aushudi Scheme besides the low marketing cost outflow .

In line with our stated philosophy and strategy, we will continue to pursue various options to achieve growth. With increase in the cost of raw material, adverse government policies and pricing guidelines, lack of modernized infrastructure and equipment, working capital constraints, inadequate cash

flows and above all, huge competition from multinationals and big brands on one side and unorganized Pharma sector on the other side, the company's growth chart is not satisfactory and the management is trying to reduce the cost and focus more on marketing tie-ups to tap the growing OTC market .

vi) INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

Your Company has adequate internal control systems commensurate with the size of its operations for the purpose of exercising adequate controls on day to day operations of the Company. Internal audit is conducted at regular intervals.

vii) FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:

The Renewal of the Manufacturing Licence of the Company is pending with the Govt authorities and the Company is getting their products manufactured on third party basis. However due to Working Capital constraints Product wise income from operations for the financial year 1st April, 2015 to 31st March, 2016 although has more than doubled, is still negligible at Rs.22.30 Lakhs.

The details of the financial performance of the Company are comprised in the Balance Sheet, Profit and Loss Account and other financial statements which are annexed hereto along with the Directors and the Auditors Report for the financial year 2015-16.

viii) HUMAN RESOURCES:

By virtue of reduction in the operations, the man power requirement has come down. There is a conscious effort by the Company to build diversity in the workforce.

Disclaimer

Some of the statements in this Management Discussion & Analysis, describing the Company's objectives, projections, estimates and expectations may be "forward looking statement" within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operation including changes in the industry structure, significant changes in political and economic environment in India, tax laws, import duties, litigation and labour relations. The Company does not undertake endeavours to update these statements.

CORPORATE GOVERNANCE REPORT

In accordance with regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the report containing the details of Corporate Governance systems and processes at Combat Drugs Limited are as follows:

1. Company's Philosophy on Code of Corporate Governance

It is the Company's endeavor to attain highest level of governance In the conduct of your Company's business and its dealings and hence ensures adherence and enforcement of the principles of corporate governance with a focus on transparency, professionalism, fairness and accountability.

The Company is continuously making efforts for improving the Corporate Governance practices in the company which can contribute substantially in achieving good governance and thus resulting in enhancement of value to its stakeholders, customers, employees, Banks, Government Agencies, etc.

The Company is committed to maintain the highest standards of Corporate Governance and adhere to the Corporate Governance requirements set out by SEBI.

2. BOARD OF DIRECTORS:

Your Company had a balanced mix of Executive and Non-Executive Directors during the year. The composition of the Board is being broadened to represent a blend of professionals from various backgrounds.

The Chairman of the Board for the first half of the financial year 2015-16 was Mr. Batula. N. Gnana Prakash, Independent Director and for the later half was Mr. BhupendraLal Waghay, Independent Director. The composition of the Board is in compliance with Regulation 25(7) Of SEBI (Listing Obligations and Disclosure Requirements) 2015.

(a) Composition and Category of Directors

The Board of Directors had an optimum combination of Two Executive and Two Non- Executive Directors one of them being a lady Director and not less than fifty percent of the Board members are Non-Executive and Independent Directors.

| Executive Directors | Age | Designation | Date of Appointment |
|----------------------------|------------|--------------------|----------------------------|
| Mr. Suchit Mohan Lal | 60 yrs. | Managing Director | 5th Aug, 1999 |
| Mr. Sushant Mohan Lal | 36 yrs. | Director | 19th May, 2006 |

Non-Executive/or Independent Directors

- | | | |
|--------------------------------------|----------------------|----------------|
| 1. Mr. Bhupendralal Waghray, 60 yrs. | Independent Director | 14th Nov, 2015 |
| 2. Mrs. Vemuri Shilpa 27 yrs. | Independent Director | 30th Mar, 2015 |

*Mr.B.N.Gnana Prakash Resigned as an Independent Director w.e.f. 14/11/2015

NOTES:

- (1) None of the Directors are related to each other except for Promoter Directors;
- (2) Number of Directorship held in other companies includes all companies, whether listed or unlisted and excludes foreign companies, other bodies corporate and professional bodies. The limits on directorship of Independent Directors and Executive Directors are within the permissible limits.
- (3) The necessary disclosures regarding change in Committee positions, if any, have been made by all the Directors, during the year under review. None of the Director is a Member of more than 10 Committees or Chairman of more than 5 Committees across all Indian companies.
- (4) Independent Director means a Non-Executive Director, who fulfils the criteria as laid down in SEBI (Listing Obligations and Disclosure Requirements) 2015
- (5) The Company has issued formal letter of appointment to its Independent Directors. The maximum tenure of Independent Directors is in accordance with the Companies Act, 2013.
- (6) The Independent Directors of the Company met every time a Board Meeting is held. These meetings are held the same day as that of the Board Meetings. In the said meetings the Independent Directors review the matters stated in SEBI (Listing Obligations and Disclosure Requirements) 2015 (b) and action items, if any, are communicated and tracked to closure to the satisfaction of Independent Directors.

Break-up of other Directorships : NIL

The Company's Independent Directors meet at least once in every financial year without the presence of Executive Directors or management personnel. Such meetings are conducted informally.

The calendar of Board meetings is decided in consultation with the Board and the schedule of such meetings is communicated to all Directors well in advance. Generally, the Board Meetings are held in Hyderabad/ Secunderabad / R.R.Dist, where the Corporate office / Registered Office of your Company is situated.

Your Board met 7 times during the financial year on 15th April, 2015, 30th May, 2015, 14th August, 2015, 29th August, 2015, 14th November, 2015, 13th February, 2016 and 31st March, 2016

The necessary quorum was present for all the Board Meetings and the Twenty Ninth Annual General Meeting. The maximum interval between any two Board Meetings was well within the maximum allowed gap of one hundred and twenty days.

After each Board Meeting, your Company has a well-articulated system of follow up, review and reporting on actions taken by the Management on the decisions of the Board and Committees of the Board.

- (b) Attendance of the Directors at the Board Meetings and the Twenty ninth AGM & Shareholding of Directors as on 31st March, 2016.

| S. No | Name | category | No. of BM Attended | Attendance at Prev. AGM | No. of M.Ships (other Co's) | Shares Held | % |
|-------|----------------------|----------------|--------------------|-------------------------|-----------------------------|-------------|-------|
| 1 | Suchit Mohan Lal | Promoter & M.D | 7 | Yes | Nil | 24,64,289 | 30.80 |
| 2 | Sushant Mohan Lal | Promoter & Dir | 7 | Yes | Nil | 20,60,491 | 24.76 |
| 3* | B.N.Gnana Praksh | Indp. Dir | 5 | No | Nil | Nil | 0.00 |
| 4 | Vemuri Shilpa | Indp. Dir | 7 | Yes | Nil | Nil | 0.00 |
| 5 | Bhupendralal Waghray | Indp. Dir | 2 | N/A | Nil | Nil | 0.00 |

*Shri B.N.gnana Prakash resigned during the year.

All changes being additions and deletions are communicated by the Board Members and recorded in the statutory registers and applicable disclosures also made to the Stock Exchanges.

The Board has constituted the following Committees and each Committee has their terms of reference as a Charter.

- (I) Audit Committee;
- (II) Nomination & Remuneration Committee
- (III) Share holders Grievance /Relationship/Share Transfer Committee

I. THE AUDIT COMMITTEE

The Audit Committee was constituted in accordance with the requirements of the Listing Agreement and reports to the Board and is primarily responsible for:

- To review the internal control systems
 - To review Quarterly and Half-yearly results
 - To review the accounting and financial policies and practices
 - To review reports furnished by the internal and statutory auditors, and ensure that suitable follow-up action is taken.
- I) The Audit Committee consists of Three Directors, as per the details given below. All Members are financially literate and have the required accounting and financial management expertise.

Mr. B.N.Gnana Prakash, Independent Director, was the Chairman of the Audit Committee and was not present at the Twenty Ninth Annual General Meeting. Mrs. Vemuri Shilpa, Independent women Director was present to answer the Shareholders' queries. The Audit committee was reconstituted on 14th November, 2015 on the Resignation of Mr. B.N.Gnana Prakash and upon inducting Mr. Bhupendralal Waghray as Independent Director who is the Chairman of the Committee at present.

The Audit Committee met 4 times during the financial year 2015-16. 30th May, 2015, 14th August 2015, 14th November, 2015, 13th February, 2016 and not more than four months had elapsed between two Audit Committee meetings. The necessary quorum was present for all the said Audit Committee Meetings.

| S.No | Name | category | Position held | No. of Meetings Attended |
|------|----------------------|----------------|---------------|--------------------------|
| 1 | Sushant Mohan Lal | Promoter & Dir | Member | 4 |
| 2* | B.N.Gnana Praksh | Indp. Dir | Chairman | 2 |
| 3 | Vemuri Shilpa | Indp. Dir | Member | 4 |
| 4 | Bhupendralal Waghray | Indp. Dir | Chairman | 2 |

*Shri B.N.Gnana Prakash resigned from the Board of directors during the year.

No sitting fees was paid to them for attending the meetings of the Board and or its Committees.

II. THE NOMINATION AND REMUNERATION COMMITTEE

The Nomination and Remuneration Committee is primarily responsible to Identify potential candidates to become Board Members besides . Recommending nominees to various Committees of the Board while Ensuring that appropriate procedures are in place to assess Board's effectiveness.

2. Developing an annual evaluation process of the Board and its Committees.
3. Devising a policy on Board diversity;
4. Assist the Board in ensuring that affordable, fair and effective compensation philosophy and policies are implemented;
5. Approve and make recommendations to the Board in respect of salary structure and actual compensation (inclusive of performance based incentives and benefits) of the Executive Directors, including the Chief Executive Officer;
6. Review and approve the overall budgetary increment proposals, disclosures in the annual report or elsewhere besides Any other matter referred to the Remuneration Committee by the Board of Directors of the Company.
7. Nomination and Remuneration Committee - salary, benefits, perquisites and allowances (fixed component) and performance incentives, commission (variable component) to its Chairman, Managing Director and other Executive Directors.

| S.No | Name | category | Position held | No. of Meetings Attended |
|------|----------------------|----------------|---------------|--------------------------|
| 1 | Sushant Mohan Lal | Promoter & Dir | Member | 3 |
| 2* | B.N.Gnana Praksh | Indp. Dir | Chairman | 2 |
| 3 | Vemuri Shilpa | Indp. Dir | Member | 3 |
| 4 | Bhupendralal Waghray | Indp. Dir | Chairman | 1 |

*The Committee was reconstituted on 14th November 2015 upon the resignation of Mr. B.N. Gnana Prakash

The Nomination and Remuneration Committee met Three times during the financial year 2015-16. They met on 30th May, 2015, 14th August, 2015 and 14th November 2015. The necessary quorum was present for all the said meetings.

Details of the Remuneration:

| Name | Designation | Yearly Remuneration (Rs). |
|------------------------------|----------------------|---------------------------|
| 1. Mr.Suchit Mohan Lal | Managing Director | 2,40,000.00. |
| 2. Mr.Sushant Mohan Lal | Executive Director | 2,40,000.00 |
| 3. Shri B.N.Gnana Prakash | Independent Director | NIL |
| 4. Smt. Vemuri Shilpa | Independent Director | NIL |
| 5. Mr. Bhupendra Lal Waghray | Independent Director | NIL |

The enhanced Remuneration of Mr.Suchit Mohan Lal, Managing Director was deferred on his request to 1st April 2016.

No sitting fee or out of pocket expenses was paid to any of the Directors during the year in view of the financial constraints and performance of the company. The Comparative Ratios are– Not applicable

III. SHAREHOLDERS' RELATIONSHIP / INVESTOR GRIEVANCE/ SHARE TRANSFER COMMITTEE

In compliance with the provisions of Section 178 of the Companies Act, 2013 and the SEBI (LODR) Regulations, 2015, the Board has constituted the committee as the "Shareholders' Relationship / Investor Grievance/ Share Transfer Committee "

The Committee reviews the following: Expeditious redressal of investor's grievances, Transfer of shares, Dematerialisation/ Re-materialisation, Non receipt of Annual Reports and declared dividend, all other matters related to shareholders Grievance & to ensure quicker investor services and expeditious disposal of the share transfer approvals. The Committee meets as and when the memorandum of transfers date is intimated by the Share Transfer Agents; VENTURE CAPITAL & CORPORATE SERVICES PRIVATE LIMITED (Registrars and Transfer Agents) and accords its approvals accordingly.

The Share Transfer Committee Met ten times during the financial year 2015-16. They met on 8th April, 2015, 27th July, 2015, 29th August, 2015, 12th September, 2015, 23rd September, 2015, 23rd November, 2015, 19th December, 2015, 23rd February, 2016, 28th March, 2016 & 31st March 2016.

| S.No | Name | category | Position held | No. of Meetings Attended |
|------|-------------------|----------------|---------------|--------------------------|
| 1 | Suchit Mohan Lal | Promoter & M.D | Chairman | 10 |
| 2 | Sushant Mohan Lal | Promoter & Dir | Member | 10 |
| 3 | Vemuri Shilpa | Indp. Dir | Member | 10 |

All the Share Transfers were effected on time and there is no share transfer pending for more than 15 days and there are No pending Share Transfers as on 31st March 2016. During the year 2015-2016, NO NEW complaint was received and as on 31/03/2016 there were no complaints pending to be resolved.

No sitting fees was paid to them for attending any meeting of the Board and or its Committees.

Your Company has a designated e-mail ID, investorinfo@combatdrugs.in for the redressal of any Stakeholders' related grievances exclusively for the purpose of registering complaints by Members/ stakeholders. Your Company has also displayed the said email ID under the investors section at its website, and other relevant details prominently for creating investor/ stakeholder awareness. Your Company maintains a functional website containing necessary information about the Company, contact information of the designated officials of the Company and the contents of the said website are updated at any given point of time as per Clause 54 of the Listing Agreement, and as per the requirements of the Companies Act, 2013.

The Compliance Officer, Mr. K Kiran Kumar monitors the share transfer process and reports to the Company's Board in each meeting and the said Officer also directly liaises with the authorities such as SEBI, Stock Exchanges, ROC etc., and investors with respect to implementation of various clause, rules, regulations and other directives of such authorities and investor service & complaints related matter. Investors may address their Communications / Suggestions / Grevieance to Mr. K Kiran Kumar at 9-109/9, Plot No.112, Gayatri Nagar, Road No.14, Boduppal, R.R.Dist - 500039. TELANGANA. India. Or send a mail to investorinfo@combatdrugs.in / cs@combatdrugs.in

3. GENERAL BODY MEETINGS :

Date, Time and Location of the last 3 Annual General Meetings are:

| AGM | Date | Location | Time |
|------|------------|--|-----------------------|
| 29th | 30.09.2015 | Plot No.112,Gayatri Nagar,Road No.14, Boduppal,R.R.District-Telengana. | 11.30 A. M. Wednesday |
| 28th | 30.09.2014 | 185, 186, Yellampet, Medchal Mandal, R.R. District, (AP) | 11.30 A.M Monday |
| 27th | 30.09.2013 | 185, 186, Yellampet, Medchal Mandal, R.R. District, (AP) | 11.30 A. M. Monday |

Postal Ballot:

No Resolution was passed during the previous year, through Postal Ballot process.

Disclosures

i) Related Party Transactions

During the year ended March 31, 2016, there were no materially significant related party transactions, which could have potential conflict with the Company's interests at large. The register of contracts / arrangements

containing the transactions in which the Directors are interested is placed before the Board regularly for its approval. Statement in summary form of transactions with related parties is placed before the audit committee for review. All related party transactions are negotiated on an arms length basis, and are intended to further the Company's interests. In compliance with regulation 53(f) of the Listing Regulations and the accounting standard 18, transactions with related parties are disclosed in the notes to accounts.

ii) Details of Non Compliance etc

The Company complied with the requirements of the Stock Exchanges, SEBI and other statutory authorities on all matters related to capital markets; no penalties or strictures were imposed on the Company by the Stock Exchanges or SEBI.

(iii) Accounting treatment in preparation of Financial Statements:

The guidelines/ accounting standards laid down by the Institute of Chartered Accountants of India (ICAI) and prescribed under Section 133 of the Companies Act, 2013 have been followed in preparation of the financial statements of the Company in all material respects.

(iv) Whistle Blower Policy: The Company has adopted a Whistle Blower Policy and has established the necessary mechanism in line with the requirements under the Companies Act, 2013 and Listing Agreement:

- For employees to report concerns about unethical behavior and to establish a mechanism to report to the management, concerns about unethical behavior, actual or suspected fraud or violation of the Integrity Policy; and
- To ensure that adequate safeguards shall be provided to the whistle blowers against any victimization or vindictive practices like retaliation, threat or any adverse (direct or indirect) action on their employment. The Policy also ensures that strict confidentiality is maintained whilst dealing with concerns and also that no discrimination will be meted out to any person for a genuinely raised concern.
- No personnel/ person has been denied access to the Audit Committee.

(v) Your Company has laid down a Code of Conduct ("Code") for all the Board Members and Senior Management Personnel of the Company. The Code is available on the website of the Company i.e., www.combatdrugs.in. All Directors and Personnel of the Company have affirmed compliance with the Company's Code of Conduct for the financial year ended March 31, 2016. A declaration signed by the Chief Executive Officer (CEO)/ Managing Director to this effect is attached as Annexure A to the Corporate Governance Report in the Annual Report.

(vi) The Company has disclosed and complied with all the mandatory requirements under SEBI (Listing Obligations and Disclosure Requirements) except the appointment of full time company secretary and Chief Financial Officer. The details of these compliances have been given in the relevant sections of this report. Among the non-mandatory requirements of SEBI (Listing Obligations and Disclosure Requirements) the Company has complied with the following:

- Separate posts of Chairman and CEO - The Chairman and Managing Director/ CEO are two separate persons -The position of Chairman and CEO is bifurcated in the Company.
- Reporting of Internal Auditor - The Internal Auditor reports directly to the Audit Committee.
- Your Company has comprehensive guidelines on prohibiting insider trading and the Company has adopted the code of internal procedures and conduct for listed companies notified by the SEBI

4. APPOINTMENT AND RE-APPOINTMENT OF DIRECTORS

A. Appointments

Mrs.Vemuri Shilpa was inducted in the Board as an Independent Woman Director from 30th September, 2015, is liable to retire by rotation & being eligible offers her candidature for Re-appointment.

Mr.Bhupendralal Waghay was inducted on the Board as an Independent Director from 14th November, 2015 and is liable to retire by rotation & being eligible offers his candidature for Re-appointment .

B. Resignations

1. Shri Batula.N.Gnana Prakash Resigned as an Independant Director w.e.f. 14th November, 2015.

5. RECONCILIATION OF SHARE CAPITAL AUDIT

The 'Reconciliation of Share Capital Audit' was undertaken on a quarterly basis and the audit covers the reconciliation of the total admitted capital with NSDL and CDSL and the total issued and listed capital. The audit has also confirmed that the aggregate of the total issued/ paid-up-capital is in agreement with the total number of shares in physical form, shares allotted & advised for demat credit but pending execution and the total number of dematerialized shares held with NSDL and CDSL.

6. SECRETARIAL AUDIT

The Auditors' Report and Secretarial Auditors' Report are given as annexure which forms part of this report.

7. MANAGEMENT DISCUSSION AND ANALYSIS

As required under SEBI (Listing Obligations and Disclosure Requirements), the Management Discussion and Analysis is provided separately in the Annual Report.

8. CEO AND CFO'S CERTIFICATION

As required by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the CEO and CFO's Certification is provided as Annexure to the Corporate Governance Report in the Annual Report. As required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the CEO and CFO's / Managing Directors Certification of the Financial Statements, the Cash Flow Statement and the Internal Control Systems for financial reporting for the financial year ended March 31, 2016, was placed before the Board of Directors at all their meetings held.

9. MEANS OF COMMUNICATION

- Company has regularly furnished Financial Results by email and also by way of filing through the electronic filing within the time lines to the Mumbai Stock Exchange.
 - Quarterly and annual financial results are also published in English, and other regional (Telugu) newspapers.
 - Website Pursuant to under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company's website www.combatdrugs.in contains all the information as may be required by the Shareholders including press releases, financial results, fact sheet reports, additional disclosures, earnings conference, shareholding pattern, Shareholders' reports, investor presentation, Annual Reports, etc., Quarterly results are put on the Company's web-site. The Company submitted a quarterly compliance report to the stock exchanges within 45 days from the close of quarter.
10. The Thirtieth Annual General Meeting (AGM) of the Company for the financial year 2015-16 is scheduled on Thursday , the 29th September, 2016 at 11.00 AM at 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Road No.14, Boduppal, R.R.Dist - 500039. TELANGANA. India.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Mumbai Stock Exchange (BSE), the Company has also extended e-voting facility, for its Members to enable them to cast their votes electronically

and also physically on the proposed resolutions in the Notice of the Thirtieth Annual AGM. Instructions for e-voting are listed under the segment “Notes” in the Notice to Thirteenth Annual AGM.

Those of the Shareholders/ Members, who cannot attend the AGM in person, can appoint a proxy to represent them in the AGM, for which the Shareholder/ Member needs to fill in a proxy form and send it to the Company, to its Registered Office address, on or before 10.30 AM on 27-09-2016.

11. GENERAL SHAREHOLDER INFORMATION:

| | |
|-----------------------------|---|
| Annual General Meeting | : 29th September, 2016 at 11.00 A.M. at 9-109/9, Plot No.112, Gayatri Nagar, Road No.14, Boduppall, R.R.Dist - 500039. TELANGANA. India. |
| Financial Year | : 1st April, 2015 to 31st March, 2016 |
| Dates of Book Closure | : 23.09.2016 to 29.09.2016 |
| Listing | : The Bombay Stock Exchange Ltd. |
| Stock Code | : 524752 |
| Registrar & Transfer Agents | : Venture Capital & Corporate Investments Pvt Ltd, 12-10-167, Bharat Nagar, Hyderabad - 500 018 Ph: +91-40+23818475 / 23818476 Fax:+91-40-23868024 E-mail:info@vccilindia.com Contact: Mr. E.S.K.Prasad / P. Srinivas Reddy |
| Share Transfer System | : The share transfers are affected within fifteen days from the date of the lodgment for transfer, transmission, sub-division, etc. and the Share Certificates are delivered to the Shareholders immediately. |
| Dematerialization of shares | : The company was allotted ISIN INE643N01012 by CDSL and NSDL and trading is being done in Dematerialized form in BSE. |
| Nomination Facility | : Shareholders, holding shares in physical form and desirous of making/ changing a nomination in respect of their shareholding in the Company as permitted under Section of the Companies Act 2013 are requested to submit |

to the Compliance Officer in the prescribed form 2B for this purpose, which can be furnished by the Company on request.

Outstanding GDR's/ ADR's/ : Nil
Warrant or any convertible instruments, conversion date and likely impact on equity.

Address for Correspondence : Registered Office : 9-109/9, Plot No.112, Gayatri Nagar, Road No.14, Boduppal, R.R.Dist - 500039. TELANGANA. India.

12. MARKET PRICE DATA

The closing market price of equity share on 31st March, 2016 (last trading day of the financial year) was Rs.6.06/- as compared to the price on 31st March 2015 of Rs.9.31 on BSE.

1. DISTRIBUTION OF SHAREHOLDING :

Distribution Details Of Shares FOR THE PERIOD 31/3/2016

| Shareholders holding nominal Value of | No. of Shareholders | | Nominal Value of Shares held and percentage of Equity | |
|---------------------------------------|---------------------|------------|---|------------|
| | Number | % To Total | Value | % To Total |
| Upto - 5000 | 11833 | 97.84 | 2856850 | 3.57 |
| 5001 - 10000 | 104 | 0.86 | 838420 | 1.05 |
| 10001 - 20000 | 56 | 0.46 | 874740 | 1.09 |
| 20001 - 30000 | 25 | 0.21 | 643560 | 0.8 |
| 30001 - 40000 | 10 | 0.08 | 340970 | 0.43 |
| 40001 - 50000 | 12 | 0.1 | 585320 | 0.73 |
| 50001 - 100000 | 20 | 0.17 | 1495560 | 1.87 |
| 100001 and above | 34 | 0.28 | 72364580 | 90.46 |
| Total | 12094 | 100 | 80000000 | 100 |

2. SHAREHOLDING PATTERN AS ON 31ST MARCH, 2016

| S. No. | Category of shareholder | Nos. of share holders | No. of equity shares held | Shareholding as a % of total no. of shares |
|------------|--|-----------------------|---------------------------|--|
| (A) | PROMOTER & PROMOTER GROUP | | | |
| | Indian Promoters: Individuals/HUF's Bodies Corporate | 7 | 5295117 | 66.19% |
| | Total Promoter Shareholding | 7 | 5295117 | 66.19% |
| (B) | NON PROMOTER / PUBLIC SHAREHOLDING | | | |
| 1 | Financial Institutions/Banks | 1 | 300 | 0.00% |
| 2 | Individual ShareHolders holding nominal share capital upto 2Lakh | 12014 | 804423 | 10.06% |
| 3 | Individual ShareHolders holding nominal share capital in excess of 2Lakh | 18 | 1600494 | 20.01% |
| 4 | Bodies Corporate | 40 | 273511 | 3.42% |
| 5 | Clearing Member | 11 | 24555 | 0.31% |
| 6 | Non Resident Individuals | 3 | 1600 | 0.02% |
| | Total Public Shareholding | | | |
| | B = (B)(1+2+3+4+5+6) | 12087 | 2704883 | 33.81% |
| | GRAND TOTAL | 12094 | 8000000 | 100.00% |

**Promoter group comprises total 5 individuals having multiple folios.*

By the Order of the Board
For **COMBAT DRUGS LIMITED**

Sd/-

SUCHIT MOHAN LAL
MANAGING DIRECTOR

Place: Hyderabad
Date: 25.08.2016

Annexure-A
TO CORPORATE GOVERNANCE

Declaration by the Managing Director under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding compliance with Code of Conduct

In accordance with under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Stock Exchanges, I hereby confirm that, all Board Members and Senior Management Personnel of the Company have affirmed compliance with the Code of Conduct, as applicable to them, for the financial year ended March 31, 2016.

By the Order of the Board
For **COMBAT DRUGS LIMITED**

Place: Hyderabad
Date: 25.08.2016

Sd/-
SUCHIT MOHAN LAL
MANAGING DIRECTOR

Annexure B to Corporate Governance
FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arms length transaction under third proviso thereto.

Details of contracts or arrangements or transactions.

| SL. No. | Particulars | Not At Arms Length | At Arms Length |
|---------|---|--------------------|---|
| 1 | Name (s) of the related party & nature of relationship | NIL | Ruchi Biotech owned by Director |
| 2 | Nature of contracts / arrangements / transaction. | NIL | Purchase of Pharmaceutical Formulations |
| 3 | Duration of the contracts / arrangements / transaction | NIL | 2015-2016 |
| 4 | Salient terms of the contracts or arrangements or transaction including the value, if any | NIL | Purchases of Rs. 21,07,400/- worth of Goods during F.Y 1st April 2015 to 31st March 2016. |
| 5 | Justification for entering into such contracts or arrangements or transactions' | NIL | N/A |
| 6 | Date of approval by the Board | NIL | 29.08.2015 |
| 7 | Amount paid as advances, if any | NIL | NIL |
| 8 | Date on which the special resolution was passed in General meeting as required under first proviso to section 188 | NIL | N/A Approved in AGM 30.09.15 |

*NOTE: The details of names, nature of relationship; nature of such contracts / arrangements / transactions are disclosed in Note No.20(iv) of the Financial Statements.

For **COMBAT DRUGS LIMITED**

Place: Hyderabad
Date: 25.08.2016

Sd/-
SUCHIT MOHAN LAL
MANAGING DIRECTOR

AUDITORS' REPORT ON CORPORATE GOVERNANCE

To
The Members of Combat Drugs Limited

We have examined the compliance of conditions of Corporate Governance by Combat Drugs Limited('the Company') for the year ended 31st March, 2016 as stipulated in Clause 49 of the Listing Agreement ('Listing Agreement') of the Company with stock exchanges for the period 1st April, 2015 to 30th November, 2015 and as per the relevant provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') as referred to in Regulation 15 (2) of the Listing Regulations for the period 1st December, 2015 to 31st March, 2016.

The compliance of condition of Corporate Governance is the responsibility of management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above-mentioned Listing Agreement / Listing Regulations as applicable.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn. No. 000125S)

Sd/-
A.V. SADASIVA
Partner
M.No. 18404

Place: Secunderabad
Date: 30th May, 2016

**CHIEF EXECUTIVE OFFICER (CEO) AND
CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION**

I Mr. Suchit Mohan Lal, CEO & Managing Director of Combat Drugs Limited to the best of my knowledge, information and belief, certify that:

- 1) We have reviewed financial statements and the cash flow statement for the year ended March 31, 2016:
 - a) These statements do not contain any materially untrue statement or omit any Material fact or contain statements that might be misleading;
 - b) These statements together present, in all material respects, a true and fair view of the Company's affairs, the financial condition and results of operations and are in compliance with applicable accounting standards, laws and regulations.
- 2) There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or which violate the Company's code of conduct.
- 3) We are responsible for establishing and maintaining internal controls over financial reporting by the Company and we have:
 - a) Designed such controls to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others;
 - b) Designed or caused to be designed, such internal control systems over financial reporting, so as to provide reasonable assurance regarding the preparation of financial statements in accordance with Generally Accepted Accounting Principles (GAAP) in India; and
 - c) Evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting.
- 4) During the year, we have disclosed to the Company's Auditors and the Audit Committee of the Board of Directors:
 - a) Any change, that has materially affected or is reasonably likely to materially affect, the Company's internal control over financial reporting;
 - b) Any significant changes in accounting policies during the year, and that the same have been disclosed appropriately in the notes to the financial statements;

- c) Instances of significant fraud, if any, that we are aware especially, if any, Member of management or employee involved in financial reporting related process. No such instances were noticed during the year 2015-16;
 - d) All significant changes and deficiencies, if any, in the design or operation of internal controls, which could adversely affect the Company's ability to record, process, summarize and report financial data; and
 - e) Any material weaknesses in internal controls over financial reporting including any corrective actions with regard to deficiencies.
- 5) In the event of any materially significant misstatements or omissions, we will return to the Company that part of any bonus or incentive which was inflated on account of such mistakes or omissions.
- 6) We affirm that we have not denied any employee, access to the Audit Committee of the Company (in respect of matters involving alleged misconduct) and we have provided protection to whistleblowers from unfair termination and other unfair or prejudicial employment practices.
- 7) We further declare that, all Board Members and Senior Managerial personnel have affirmed compliance with the code of conduct for the current year.

For COMBAT DRUGS LIMITED

Sd/-

SUCHIT MOHANLAL
MANAGING DIRECTOR

Place: Hyderabad

Date:25.08.2016

Form MR-3
SECRETARIAL AUDIT REPORT

[Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and
Remuneration Personnel) Rules, 2014]
FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2016

To
The Members of
M/s. Combat Drugs Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Combat Drugs Limited (hereinafter called "the Company").

Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon. Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2015 and ended 31st March, 2016, complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter :

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by M/s. Combat Drugs Limited ("The Company") for the financial year ended on 31st March, 2016, according to the provisions of:
 - i. The Companies Act, 2013 (the Act) and the rules made thereunder for specified sections notified and came into effect from 12th September, 2013 and sections and Rules notified and came into effect from 1st April, 2014;
 - ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder; 47
 - iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
 - iv. Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment (FDI), Overseas Direct Investment, and External Commercial Borrowings (not applicable during the audit period);

- v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):
- i. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
 - ii. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client;
 - iii. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - iv. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
 - v. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009;
 - vi. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998;
 - vii. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008
 - viii. The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999;
- vi) Other applicable laws, including the following:
- (a) Factories Act, 1948
 - (b) Payment of Gratuity Act, 1972
 - (c) Employees Provident Fund and Miscellaneous provisions Act, 1952
 - (d) Employees State Insurance Act 1948
 - (e) Maternity Benefit Act, 1961
 - (f) Minimum Wages Act, 1948
 - (g) Payment of Bonus Act, 1972
 - (h) Payment of Wages Act 1936
 - (i) Industrial Dispute Act, 1947
 - (j) Environment (Protection) Act, 1986
 - (k) Legal Metrology Act, 2009
 - (l) Competition Act, 2002
 - (m) Income-tax Act 1961
 - (n) Indian Stamp Act, 1899
 - (o) The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013
 - (p) Drugs and Cosmetics Act, 1940

3. We have also examined compliance with the applicable clauses of the following:
 - i. Secretarial Standards issued by The Institute of Company Secretaries of India to the extent applicable under the provisions of Companies Act, 2013 and
 - ii. The Listing Agreements entered into by the Company with the Bombay Stock Exchange Limited;
4. We further report that :
 - (a) The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the year under review were carried out in compliance with the provisions of the Companies Act, 2013.
 - (b) Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation of the meeting.
 - (c) Majority decision is carried through while the dissenting members' views, if any, are captured and recorded as part of the minutes.
5. We further report that there are adequate systems and processes in the Company with the size and operation of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
6. We further report that during the audit period :
 - i) The company's manufacturing licence under the Drugs and Cosmetics Act, 1940 is under renewal.
 - ii) The company has not paid dues of professional tax for the period under review. We are informed by the company that efforts are being to clear the dues.

Place: Hyderabad,
Date: 24th August, 2016

For MARTHI & CO,
Company Secretaries
Sd/-
S S MARTHI
PROPRIETOR
FCS 1989, CP 1937

ANNEXURE - F

Form No. MGT-9 EXTRACT OF ANNUAL RETURN AS ON THE FINANCIAL YEAR ENDED ON 31ST MARCH 2016

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

- i. CIN : CL23230TG1986PLC006781
ii. Registration Date : 17-09-1986
iii. Name of the Company : COMBAT DRUGS LIMITED
iv. Category / Sub-Category of the Company : Company Limited by shares and Indian Non-Government Company
v. Address of the Registered office and contact details As per Last Year annual Return : 9-109/9, Plot No.112, Gayatri Nagar Rd., No.14, Boduppal, R.R.Dist - 500039. TELANGANA. India.
vi. Whether listed company : Yes
vii. Name, Address and Contact details of Registrar and Transfer Agent, if any : M/s Venture Capital & Corporate Services Pvt Ltd 12-10-167, Bharat Nagar, Hyderabad-500 018, Telangana.
Phone: (+91)-4023818475/476
Fax: +91 40 23868024
Email Id: Info@Vccipl.Com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

| S No. | Name and Description of main products / services | NIC Code of the Product/ service | % of Total Turnover of the Company |
|-------|--|----------------------------------|------------------------------------|
| 1 | Manufacturing & Trading | 21002 | 100% |

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

| S No. | Name and Description of main products / services | CIN/GLN | Holding/ Subsidiary / Associate | % of Shares Held | Applicable Section |
|-------|--|---------|---------------------------------|------------------|--------------------|
| | NIL | | | | |

I. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i. Category-wise Share Holding

| S.No. | Category of shareholder | No. of Shares held at beginning of the | | | | No. of Shares held at End of the Year | | | | % change during the year |
|-------|--|--|----------------|----------------|------------------------|---------------------------------------|----------------|----------------|------------------------|--------------------------|
| | | Demat | Physical | Total | As a % of total Shares | Demat | Physical | Total | As a % of total Shares | |
| (A) | PROMOTER & PROMOTER GROUP | | | | | | | | | |
| | Indian Promoters: Individuals/HUF's / Bodies Corporate | 5294567 | 550 | 5295117 | 66.19% | 5294567 | 550 | 5295117 | 66.19% | 0.00% |
| | Total Promoter Shareholding | 5294567 | 550 | 5295117 | 66.19% | 5294567 | 550 | 5295117 | 66.19% | 0.00% |
| (B) | NON PROMOTER / PUBLIC SHAREHOLDING | | | | | | | | | |
| 1 | Institutions | | | | | | | | | |
| a | Financial Institutions/Banks | 0 | 300 | 300 | 0.00% | 0 | 300 | 300 | 0.00% | 0.00% |
| | Sub Total - B1 | 0 | 300 | 300 | 0.00% | 0 | 300 | 300 | 0.00% | 0.00% |
| 2 | Non Institutions | | | | | | | | | |
| a | Individual ShareHolders holding nominal share capital upto 2Lakh | 437010 | 283551 | 720561 | 9.01% | 512372 | 292051 | 804423 | 10.06% | 1.05% |
| b | Individual ShareHolders holding nominal share capital in excess of 2Lakh | 736015 | 663341 | 1399356 | 17.49% | 712880 | 887614 | 1600494 | 20.01% | 2.51% |
| c | Bodies Corporate | 98792 | 467703 | 566495 | 7.08% | 65081 | 208430 | 273511 | 3.42% | -3.66% |
| d | Clearing Member | 17571 | 0 | 17571 | 0.22% | 24555 | 0 | 24555 | 0.31% | 0.09% |
| e | Non Resident Individuals | 600 | 0 | 600 | 0.01% | 1600 | 0 | 1600 | 0.02% | 0.01% |
| | Sub Total - B2 | 1289988 | 1414595 | 2704583 | 33.81% | 1316488 | 1388095 | 2704583 | 33.81% | 0.00% |
| | Total Public Shareholding B = (B1 + B2) | 1289988 | 1414895 | 2704883 | 33.81% | 1316488 | 1388395 | 2704883 | 33.81% | 0.00% |
| | GRAND TOTAL | 6584555 | 1415445 | 8000000 | 100.00% | 6811055 | 1388945 | 8000000 | 100.00% | 0.00% |

ii. Shareholding of Promoters

| S.No. | Shareholder Name | Holding at beginning of the Year | | | Holding at End of the Year | | | % change during the year |
|-------|-------------------|----------------------------------|---------------|-----------|----------------------------|---------------|-----------|--------------------------|
| | | No. of Shares | % of Equity | % pledged | No. of Shares | % of Equity | % pledged | |
| 1 | Suchit Mohan Lal | 2464289 | 30.80% | 0 | 2464289 | 30.80% | 0 | 0.00% |
| 2 | Sushant Mohan Lal | 2060491 | 25.76% | 0 | 2060491 | 25.76% | 0 | 0.00% |
| 3 | Anita Mathur | 714787 | 8.93% | 0 | 714787 | 8.93% | 0 | 0.00% |
| 4 | Ruchi Mathur | 550 | 0.01% | 0 | 550 | 0.01% | 0 | 0.00% |
| 5 | Ankita Mathur | 55000 | 0.69% | 0 | 55000 | 0.69% | 0 | 0.00% |
| | Total | 5295117 | 66.19% | 0 | 5295117 | 66.19% | 0 | NIL |

*Total number of folios of promoters is seven

iii. Change in Promoters' Shareholding (please specify, if there is no change)
There is no Change in Promoter Holding during the Financial year.

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment.

| | Secured Loans excluding deposits | Unsecured Loans | Deposits | Total |
|---|----------------------------------|-----------------|----------|-------|
| Indebtedness at the beginning of the financial year | | | | |
| i) Principal Amount | | | | |
| ii) Interest due but not paid | Nil | Nil | Nil | Nil |
| iii) Interest accrued but not | - | - | - | - |
| Total (i+ii+iii) | Nil | Nil | Nil | Nil |
| Change in Indebtedness during the financial year | | | | |
| - Addition | - | - | - | - |
| - Reduction | - | - | - | - |
| Net Change | - | - | - | - |
| Indebtedness at the end of the financial year | Nil | Nil | Nil | Nil |
| i) Principal Amount | - | - | - | - |
| ii) Interest due but not paid | - | - | - | - |
| iii) Interest accrued but not due | - | - | - | - |
| Total (i+ii+iii) | Nil | Nil | Nil | Nil |

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager

| Sl. No. | Particulars of Remuneration | Name of MD/WTD/ Manager | | | | Total Amount |
|---------|---|------------------------------|--------------------------------|-----|----|----------------------|
| 1. | Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 | MD Suchit Mohan Lal | WTD Sushant Mohan Lal | MAN | | 2,40,000 2,40,000 |
| | (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 | | | | | |
| | (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961 | | | | | |
| 2. | Stock Option | NIL | -- | NIL | -- | NIL |
| 3. | Sweat Equity | NIL | | NIL | | NIL |
| 4. | Commission - as % of profit - others, specify... | NIL | | NIL | | NIL |
| 5. | Others, please specify | NIL | | NIL | | NIL |
| 6. | Total (A) | NIL | | NIL | | 4,80,000 |
| | Ceiling as per the Act | | | | | |

B. Remuneration to other directors:

Independent Directors • Fee for attending board committee meetings Nil

| Sl. No. | Particulars of Remuneration | Name of MD/WTD/ Manager | | | | Total Amount |
|---------|--|-------------------------|-----|-----|-----|--------------|
| | Independent Directors • Fee for attending board committee meetings • Commission • Others, please specify | Nil | | | | Nil |
| | Total (1) Other Non-Executive Directors • Fee for attending board committee meetings • Commission • Others, please specify | Nil | | | | Nil |
| | Total (2) | Nil | | | | Nil |
| | Total (B)=(1+2) | Nil | | | | Nil |
| | Total Managerial Remuneration | Nil | Nil | Nil | Nil | |
| | Overall Ceiling as per the Act | | | | | |

C. Remuneration to Key Managerial Personnel Other Than MD /Manager / WTD

| Sl. No. | Particulars of Remuneration | Key Managerial Personnel | | | |
|-----------|--|--------------------------|-------------------|------------|------------|
| | | CEO | Company Secretary | CFO | Total |
| 1. | Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961 | NIL | NIL | NIL | NIL |
| 2. | Stock Option | | | | |
| 3. | Sweat Equity | | | | |
| 4. | Commission - as % of profit - others, specify... | | | | |
| 5. | Others, please specify | | | | |
| 6. | Total | NIL | NIL | NIL | NIL |

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

| Type | Section of the companies Act | Brief description | Details of Penalty/ Punishment/ Compounding fees imposed | Authority [RD/ /NCLT/ Court] | Appeal made. If any (give details) |
|-------------------------------------|------------------------------|-------------------|--|------------------------------|------------------------------------|
| A. Company | | | | | |
| Penalty | | | | | |
| Punishment | | | | | |
| Compounding | | NIL | NIL | NIL | |
| B. Directors | | | | | |
| Penalty | | NIL | NIL | NIL | |
| Punishment | | | | | |
| Compounding | | | | | |
| C. Other Officers In Default | | | | | |
| Penalty | | NIL | NIL | NIL | |
| Punishment | | | | | |
| Compounding | | | | | |

INDEPENDENT AUDITORS' REPORT

To
The Members of Combat Drugs Limited

Report on the Financial Statements

We have audited the accompanying financial statements of Combat Drugs Limited("the Company"), which comprise the Balance Sheet as at 31st March, 2016, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2016, and its profit and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure A, statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March, 2016 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2016 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i) The Company does not have any pending litigations which would impact its financial position;
 - ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Sd/-

A.V.Sadasiva
Partner - M.No.018404

Place: Secunderabad.
Date: 30th May' 2016.

Annexure - A to the Auditors' Report

The Annexure referred to in our report to the members of the Company for the year ended on 31st March, 2016. We report that:

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) As explained to us, the fixed assets have been physically verified by the management in a periodical manner, which in our opinion is reasonable, having regard to the size of the company and the nature of its business. No material discrepancies were noticed on such physical verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no immovable properties were held by the Company.
- (ii) The inventories have been physically verified during the year by the management. The discrepancies noticed on verification between the physical stocks and book records were not material.
- (iii) The company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under section 189 of the Act. Accordingly, paragraph 3 (iii) (a) to (c) of the Order is not applicable.
- (iv) In our opinion and according to the information and explanations given to us, the Company has no transactions with regard to the provisions of Section 185 and 186 of the Act, with respect to loans, investments, guarantees and securities made.
- (v) The Company has not accepted deposits within the meaning of the provisions of sections 73 to 76 or any other relevant provisions of the Act and the rules framed there under.
- (vi) Maintenance of cost records by the company has not been prescribed by Central Government of India under sub-section (1) of section 148 of the Companies Act, 2013. Accordingly, paragraph 3 (vi) of the Order is not applicable.
- (vii) (a) According to the information and explanations given to us and the records of the Company examined by us, the Company is regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales-tax, value added tax, wealth tax, service tax, customs duty, excise duty, cess and any other statutory dues as applicable with the appropriate authorities and there were no arrears of outstanding statutory dues as at the last day of the financial year concerned for a period of more than six months from the date they became payable except an amount of Rs. 38979/- due with respect to Professional tax for more than six months.
- (b) According to the information and explanations given to us and records of the Company examined by us, there are no disputes pending against the company as at 31st March, 2016.

- (viii) The Company has not taken any loans or borrowing to a financial institution, banks and Governments. Accordingly, paragraph 3 (viii) of the Order is not applicable.
- (ix) The Company did not raise any money by way of initial public offer or further public offer during the year. In our opinion and according to the information and explanations given to us, the term loans have been applied for the purpose for which the loans were obtained other than amounts temporarily invested pending utilization of the funds for the intended use.
- (x) To the best of our knowledge and belief and according to the information and explanations given to us, no fraud on or by the Company was noticed or reported during the year.
- (xi) According to the information and explanations give to us and based on our examination of the records of the Company, the Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
- (xii) In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly, paragraph 3 (xii) of the Order is not applicable.
- (xiii) According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with section 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3 (xv) of the Order is not applicable.
- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Sd/-

A.V.Sadasiva

Partner - M.No.018404

Place: Secunderabad.

Date: 30th May' 2016.

Annexure - B to the Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Combat Drugs Limited ("the Company") as of 31 March 2016 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2016, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For M. Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Sd/-

A.V.Sadasiva

Partner - M.No.018404

Place: Secunderabad.

Date: 30th May' 2016.

COMBAT DRUGS LIMITED
Balance Sheet as at March 31, 2016

| Particulars | Note | 2016 | 2015 |
|--|------|-------------------|-------------------|
| I EQUITY AND LIABILITIES | | | |
| Shareholders' Funds | | | |
| a) Share capital | 2 | 80,000,000 | 80,000,000 |
| b) Reserves and Surplus | 3 | (58,778,415) | (46,000,532) |
| Current Liabilities | | | |
| a) Trade payables | | | |
| Total outstanding dues of micro enterprises and small enterprises | | - | - |
| Total outstanding dues of creditors other than micro enterprises and small enterprises | 4 | 3,926,561 | 2,542,936 |
| b) Other current liabilities | 5 | 924,489 | 1,997,811 |
| TOTAL | | 26,072,635 | 38,540,215 |
| II. ASSETS | | | |
| Non-Current Assets | | | |
| a) Fixed Assets | | | |
| Tangible | 6 | - | 8,588,724 |
| b) Long term loans and advances | 7 | 22,165,388 | 22,165,388 |
| Current Assets | | | |
| a) Inventories | 8 | 2,102,394 | 5,015,609 |
| b) Trade Receivables | 9 | 718,179 | 805,338 |
| c) Cash and Cash equivalents | 10 | 27,894 | 976,368 |
| d) Short term loans and advances | 11 | 1,058,780 | 988,788 |
| TOTAL | | 26,072,635 | 38,540,215 |
| Significant Accounting policies | 1 | - | - |

The accompanying notes form an integral part of the financial statements
As per our report of even date

For M. ANANDAM & CO

Chartered Accountants

Sd/-

A V Sadasiva

Partner

M No: 018404

For and on behalf of the Board

Sd/-

Suchit Mohal Lal

Managing Director

Sd/-

Sushant Mohan Lal

Director

Place: Secunderabad

Date : 30.05.2016

COMBAT DRUGS LIMITED
Statement of Profit & Loss for the year ended March 31, 2016

| Particulars | Note | 2016 | 2015 |
|---|------|---------------------|---------------------|
| Income | | | |
| I. Revenue from operations | 12 | 2,229,879 | 963,247 |
| II. Other income | 13 | 54,570 | 877,252 |
| III. Total Revenue (I+II) | | 2,284,449 | 1,840,499 |
| IV. Expenses | | | |
| Cost of Materials Consumed | 14 | 1,131,042 | 948,675 |
| Employee Benefit Expenses | 15 | 1,237,500 | 777,000 |
| Other Expenses | 16 | 11,837,740 | 1,155,549 |
| Depreciation | 6 | 856,050 | 2,320,759 |
| Total Expenses | | 15,062,332 | 5,201,983 |
| V. Profit / (Loss) before Exceptional items and Tax (III-IV) | | | |
| Exceptional items | 18 | - | 33,476,960 |
| VI. Profit / (Loss) before tax | | (12,777,883) | (36,838,444) |
| Tax expense | | | |
| a) Current tax | | - | - |
| b) Deffered tax | | - | - |
| VII. Profit / (Loss) for the yaer | | (12,777,883) | (36,838,444) |
| VIII. Earnings Per share | | | |
| (Face Value Rs.10 each) | 19 | | |
| - Basic | | (1.60) | (4.60) |
| - Diluted | | (1.60) | (4.60) |

Significant Accounting policies 1

The accompanying notes form an integral part of the financial statements
As per our report of even date

For M. ANANDAM & CO

Chartered Accountants

Sd/-

A V Sadasiva

Partner

M No: 018404

For and on behalf of the Board

Sd/-

Suchit Mohal Lal

Managing Director

Sd/-

Sushant Mohan Lal

Director

Place: Secunderabad

Date : 30.05.2016

NOTE.1: Significant Accounting Policies

- a) **Basis of Preparation of financial statements** : These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India ("Indian GAAP") to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules 2014, and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared under the historical cost convention on accrual basis.
- b) **Revenue Recognition** : Revenue is recognized on accrual basis. Revenue from sale of goods is recognised when the significant risks and rewards are transferred to the customers, usually on delivery of the goods.
- c) **Fixed Assets** : The fixed assets are stated at cost of acquisition and subsequent improvements thereto including taxes duties, freight and other incidental expenses related to acquisition and installation.
- d) **Depreciation** : Depreciation on tangible assets is provided on the straight line method and at the useful life and in the manner specified in Schedule II of the Companies Act, 2013. For assets acquired or disposed off during the year, depreciation is provided on prorata basis.
- e) **Deferred tax liability / Asset** : To provide and recognize Deferred tax on timing differences between taxable income and accounting income subject to consideration of prudence.
- f) **Inventories** :
- i) Inventories are valued at lower of the cost or net realizable value.
 - ii) Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of acquisition and estimated costs necessary to make the sale.
- g) **Earnings per share** : Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period are adjusted for events of bonus issue and share split, if any. For the purpose of calculating diluted earnings per share, the net profit for the year attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares
- h) **Provisions, Contingent Liabilities and Contingent Assets** : Provisions are recognized when the Company has a legal and constructive obligation as a result of a past event, for which it is probable that a cash outflow will be required and a reliable estimate can be made of the amount of the obligation. Contingent Liabilities are disclosed when the Company has possible obligation or a present obligation and it is probable that a cash outflow will not be required to settle the obligation.

Note 2: Share Capital

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|--|------------------|------------------|
| AUTHORIZED | | |
| 80,00,000 Equity Shares of Rs.10/- each (Previous year 80,00,000 Equity Shares of Rs.10/- each) | 80,000,000 | 80,000,000 |
| ISSUED AND SUBSCRIBED | | |
| 80,00,000 Equity Shares of Rs.10/- each (Previous year 80,00,000 Equity Shares of Rs.10/- each) | 80,000,000 | 80,000,000 |
| PAID UP : | | |
| 80,00,000 Equity Shares of Rs.10/- each (Previous year 80,00,000 Equity Shares of Rs.10/- each) | 80,000,000 | 80,000,000 |

2.1 Rights attached to equity shares

The Company has only one class of equity shares having a face value of Rs.10 /- each. Each holder of equity share is entitled to one vote per share. The company declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the equity shareholders will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

2.2 The details of shareholders holding more than 5%

| Name of the shareholder | 31st March, 2016 | | 31st March, 2015 | |
|-------------------------|------------------|--------------|------------------|--------------|
| | No. of Shares | % holding | No. of Shares | % holding |
| Suchit Mohan Lal | 2,464,289 | 30.80 | 2,464,289 | 30.80 |
| Sushant Mohan Lal | 2,060,491 | 25.76 | 2,060,491 | 25.76 |
| Anitha Mathur | 714,787 | 8.93 | 714,787 | 8.93 |
| | 5,239,567 | 65.49 | 5,239,567 | 65.49 |

2.3 The reconciliation of the number of shares as at 31st March 2016 is set out below :

| Particulars | 31st March, 2016 | 31st March, 2015 |
|---|---------------------|---------------------|
| Number of shares at the beginning of the year | 5,239,567.00 | 5,239,567.00 |
| Add: Shares issued during the year | - | - |
| Number of shares as at the end of the year | 5,239,567.00 | 5,239,567.00 |

Note 3: Reserves & Surplus

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|--|---------------------|---------------------|
| Surplus / (Deficit) | | |
| Opening balance | (46,000,532) | (9,162,088) |
| Add: Net profit/(loss) transferred from Statement of Profit & Loss | (12,777,883) | (36,838,444) |
| Closing Balance | (58,778,415) | (46,000,532) |

NOTE 4: Trade Payables

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|-------------------------------------|------------------|------------------|
| Dues to Micro and Small enterprises | - | - |
| Others | 3,926,561 | 2,542,936 |
| TOTAL | 3,926,561 | 2,542,936 |

4.1 As per available information with the Company, there are no dues to micro and small enterprises.

NOTE 5: Other Current Liabilities

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|-------------------------|------------------|------------------|
| Statutory Liabilities | 38,979 | - |
| Expenses payable | 885,510 | 997,811 |
| Advances from customers | - | 1,000,000 |
| TOTAL | 924,489 | 1,997,811 |

5.1 Statutory Liabilities include Professional Tax

COMBAT DRUGS LIMITED

Note - 6: FIXED ASSETS

(Amount in Rs.)

| Sl. No. | Name of the Asset | GROSS BLOCK | | | DEPRECIATION | | | NET BLOCK | | |
|---------|---------------------|-------------------|-----------|---------------------------|-------------------|-------------------|-------------------|---------------------------|-------------------|-------------------|
| | | As At 31.03.15 | Additions | Deletions/ Adjustments | As At 31.03.16 | As On 31.03.15 | For the Year | Deletions/ Adjustments | As On 31.03.16 | As At 31.03.15 |
| 1 | Leased Building | 31,268,074 | - | 31,268,074 | - | 31,268,074 | - | - | - | - |
| 2 | Furniture | 454,723 | - | 454,723 | 454,723 | - | - | 454,723 | - | - |
| 3 | Computers | 492,700 | - | 492,700 | 492,700 | - | - | 492,700 | - | - |
| 4 | Plant & Machinery | 17,121,409 | - | 17,121,409 | 8,532,685 | 856,050 | 9,388,735 | - | - | 8,588,724 |
| 5 | Lab Equipment | 1,032,911 | - | 1,032,911 | 1,032,911 | - | 1,032,911 | - | - | - |
| 6 | Office Equipment | 291,815 | - | 291,815 | 291,815 | - | - | 291,815 | - | - |
| 7 | Electrical Fittings | 1,678,251 | - | 1,678,251 | 1,678,251 | - | 1,678,251 | - | - | - |
| | Total Rs. | 52,339,883 | - | 51,100,645 | 1,239,238 | 856,050 | 43,367,971 | 1,239,238 | - | 8,588,724 |
| | Previous Year | 52,339,883 | - | - | 11,743,440 | 2,320,759 | 29,686,960 | 43,751,159 | 8,588,724 | 40,596,443 |

NOTE 7: Long Term Loans and Advances

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|------------------------------|-------------------|-------------------|
| Deposit - Buildings | 12,000,000 | 12,000,000 |
| Deposit - Electricity | 139,394 | 139,394 |
| Deposit - Excise Authorities | 15,000 | 15,000 |
| Deposit - Machinery | 10,000,000 | 10,000,000 |
| Deposit - VAT | 3,000 | 3,000 |
| Deposit - Telephones | 7,994 | 7,994 |
| TOTAL | 22,165,388 | 22,165,388 |

NOTE 8: Inventories

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|----------------------------|------------------|------------------|
| Raw materials & Excepients | - | 257,002 |
| Packing materials | 623,594 | 623,594 |
| In process formulations | - | 2,881,213 |
| Finished formulations | 1,478,800 | 1,253,800 |
| TOTAL | 2,102,394 | 5,015,609 |

8.1 Expired stocks of Raw Materials Written off to the extent of Rs. 11,10,879/- (P.Y. Rs.37,90,000/-) respectively

NOTE 9: Trade Receivables

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|--|------------------|------------------|
| Unsecured, Considered good : | | |
| a) Outstanding for a period exceeding six months | 566,367 | 612,135 |
| b) Others | 151,812 | 193,203 |
| TOTAL | 718,179 | 805,338 |

NOTE 10: Cash and Cash equivalents

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|---------------------------|------------------|------------------|
| Cash and Cash equivalents | | |
| a) Cash on Hand | 7,175 | 3,787 |
| b) Balances with Banks | 20,727 | 972,582 |
| TOTAL | 27,902 | 976,369 |

NOTE 11: Short Term Loans and Advances

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|------------------------------------|------------------|------------------|
| Advances to Staff | 100,000 | 100,000 |
| Advances to Suppliers | 145,023 | 75,023 |
| Cenvat Credit available and others | 813,754 | 813,754 |
| VAT Input Credit available | 3 | 11 |
| TOTAL | 1,058,780 | 988,788 |

NOTE 12: SALES

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|--------------|------------------|------------------|
| Pharma Sales | 2,229,879 | 963,247 |
| TOTAL | 2,229,879 | 963,247 |

NOTE 13: Other Income

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|--------------|------------------|------------------|
| Scrap Sales | 54,570 | 877,252 |
| TOTAL | 54,570 | 877,252 |

NOTE 14: Cost of Material Consumed

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|--------------------------|------------------|------------------|
| Opening stock | 5,015,609 | 8,790,609 |
| Add: Purchases | 2,209,919 | 963,675 |
| Less: Closing stock | 2,102,394 | 5,015,609 |
| Less: Stocks written off | 3,992,092 | 3,790,000 |
| TOTAL | 1,131,042 | 948,675 |

NOTE 15: Employee Benefits

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|-------------------------|------------------|------------------|
| Directors' Remuneration | 480,000 | 480,000 |
| Salaries to Staff | 738,000 | 297,000 |
| Staff welfare | 19,500 | - |
| TOTAL | 1,237,500 | 777,000 |

NOTE 16: Other Expenditure

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|----------------------------------|-------------------|------------------|
| Advertisement expenses | 42,680 | 13,980 |
| Audit Fees | 40,075 | 28,090 |
| Bank & Service Charges | 1,157 | 709 |
| Consultancy & Other Charges | 186,577 | 200,024 |
| Conveyance & Vehicle Maintenance | 361,559 | 192,500 |
| Fuel, Power & Light | - | 78,000 |
| Legal expenses | 12,500 | - |
| Loss on sale of fixed assets | 6,165,174 | - |
| Office Expenses | 57,216 | 109,113 |
| Postage & Telegrams | 298,002 | 112,880 |
| Printing & Stationery | 118,200 | 147,500 |
| Rent | 213,000 | 60,000 |
| Rates & Taxes | 254,636 | 186,299 |
| Repairs & Maintenance | 5,187 | - |
| Telephone expenses | 18,199 | - |
| Travelling - Directors & Others | 71,486 | 26,454 |
| Expired Stocks | 3,992,092 | - |
| TOTAL | 11,837,740 | 1,155,549 |

NOTE 17: Auditors Remuneration

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|-----------------------|------------------|------------------|
| a) As Auditor | | |
| For Statutory Audit | 40,075 | 28,090 |
| b) For Other Services | - | - |
| TOTAL | 40,075 | 28,090 |

NOTE 18: Exceptional items

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|-----------------------------|------------------|-------------------|
| Obsolete stocks written off | - | 3,790,000 |
| Fixed assets written off | - | 29,686,960 |
| TOTAL | - | 33,476,960 |

NOTE 19: Earnings Per Share

(Amount in Rs.)

| Particulars | 31st March, 2016 | 31st March, 2015 |
|-------------------------------------|------------------|------------------|
| Profit / (Loss) after tax | (12,777,883) | (36,838,444) |
| Equity Shares (in Number) | 8,000,000 | 8,000,000 |
| Basic and Diluted Earning Per Share | (1.60) | (4.60) |
| Face value per share | 10 | 10 |

NOTE 20: Related Party Disclosures as per AS 18 read with the Companies Act, 2013

i) Key Managerial Personnel (KMP):

Suchit Mohan Lal - Managing Director
Sushanth Mohan Lal - Director

ii) Non Whole time Directors:

Vemuri Shilpa
Bhupendra Lal Waghay

iii) Enterprises in which key managerial personnel and/or their relatives have control:

Ruchi Bio Tech (Sushanth Mohan Lal - Proprietor)

iv) Aggregated Related Party Disclosures:

(Amount in Rs.)

| Nature of Transaction | Key managerial personnel | Enterprises Controlled by KMP /Relatives of KMP | Total |
|---|--------------------------|---|-------------|
| Remuneration | 480,000.00 | - | 480,000.0 |
| Purchase of Goods (from Ruchi Bio Tech) | - | 2,107,400.00 | 2,107,400.0 |

NOTE 21: Other Disclosuers

| Particulars | 31st March, 2016 | 31st March, 2015 |
|-------------------------------|------------------|------------------|
| Foreign Currency Expenditure | Nil | Nil |
| Income in Foreign Currency | Nil | Nil |
| Capital and Other Commitments | Nil | Nil |
| Contingent Liabilities | Nil | Nil |

NOTE 22: Figures for the previous year are reclassified /regrouped and rearranged wherever necessary.

COMBAT DRUGS LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH 2016

| Particulars | 2016 | 2015 |
|--|--------------------|--------------------|
| Cash Flows from Operating Activities | | |
| Net profit before tax and extraordinary items | (12,777,883) | (36,838,444) |
| Adjustments for : | | |
| Depreciation | 856,050 | 2,320,759 |
| Loss on sale of fixed assets | 6,165,174 | 29,686,960 |
| Operating profit before working capital changes | (5,756,659) | (4,830,725) |
| Adjustments for : | | |
| (Increase)/Decrease in Trade and Other Receivables | 87,159 | 2,918,152 |
| (Increase)/Decrease in Inventories | 2,913,215 | 3,775,000 |
| (Increase)/Decrease in Loans and Advances | (69,992) | 3,008,087 |
| Increase/(Decrease) in liabilities and Provisions | 310,303 | (3,908,440) |
| Cash generated from operations | (2,515,974) | 962,074 |
| Taxes Paid | - | - |
| Net Cash from operating activities | (2,515,974) | 962,074 |
| Cash flows from Investing Activities | | |
| Sale of Plant and Machinery | 1,567,500 | - |
| Net Cash flows from Investing Activities | 1,567,500 | - |
| Cash flows from Financing Activities | - | - |
| Net Increase in cash and cash equivalents | (948,474) | 962,074 |
| Cash and Cash equivalents at the beginning of the year | 976,368 | 14,294 |
| Cash and Cash equivalents at the ending of the year | 27,894 | 976,368 |

The accompanying notes form an integral part of the financial statements
As per our report of even date

For M. ANANDAM & CO

Chartered Accountants

Sd/-

A V Sadasiva

Partner

M No: 018404

For and on behalf of the Board

Sd/-

Suchit Mohal Lal

Managing Director

Sd/-

Sushant Mohan Lal

Director

Place: Secunderabad

Date : 30.05.2016

COMBAT DRUGS LIMITED

Regd. Off: 9-109/9, Plot No.112, Rd.No.14, Gayatri Nagar,
Boduppal, R.R.Dist - 500039. TS.

The Ministry of Corporate Affairs (MCA) has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the Companies vide its circular no. 17/2011 dated April 21, 2011 and 18/ 2011 dated April 29, 2011 after considering certain provisions of the Information Technology Act, 2000, permitted the companies to send the notices / annual reports etc. through email to its members. To support this green initiative of the MCA whole heartedly, members who have not yet registered their email address, are requested to register their e-mail address with the Depository through their concerned Depository Participant and members who hold shares in physical mode are requested to intimate their e-mail address at which they would like to receive the above documents electronically, either to the company or to its Registrar and ShareTransfer Agent. Shareholders are requested to fill the consent form below and send it to the Registrar and Share Transfer Agent, M/s Venture Capital & Corporate Investments Private Limited or to the company.

CONSENT FOR RECEIVING DOCUMENTS IN ELECTRONIC MODE

(Pursuant to circulars no. 17/2011 dated April 21, 2011 and 18/2011 Dtd April 29, 2011)

To

M/S Venture Capital & Corporate Services Private Limited

12-10-167, Bharat Nagar, Hyderabad-500 018, Telangana

Email id: info@vccipl.com

Dear Sir,

I/We shareholder (s) of COMBAT DRUGS LIMITED, agree to receive all notices and documents including the Annual Report, Notice for General Meetings and other Shareholders Communication in electronic mode (through email).

I/We request you to kindly register my / our below mentioned email id in the company's records for sending such communication through email.

Folio No /DP ID No.*.....Client ID No.*.....

*Applicable for members holding shares in electronic form.

Name of the Sole / First Shareholder : _____

Name of the Joint Shareholders (if any) : _____

No. of Shares held : _____

E-mail id for receipt of documents in Electronic mode : _____

Date :

Place :

Signature:

(Sole / First Shareholder)

Note:

1. Shareholders are requested to inform the Company's Registrar and Share Transfer Agents Venture Capital & Corporate Investments Pvt Ltd, as and when there is change in their registered email-id.
2. For shares held in demat form, shareholders are also requested to inform /update their email-ids to their respective Depository Participants.

COMBAT DRUGS LIMITED

Regd. Off: 9-109/9, Plot No.112, Rd.No.14, Gayatri Nagar, Boduppall, R.R.Dist - 500039. TS.

ATTENDANCE SLIP: 30th ANNUAL GENERAL MEETING on 29th SEPTEMBER, 2016

Regd. Folio No.:..... No. of Shares: **MEMBER / PROXY**

DP ID No.:..... Client ID No.:

I hereby record my presence at the 30th ANNUAL GENERAL MEETING of the Members of the Company held on 29th September, 2016 at 11.00 A.M at 9-109/9, Plot No.112, Gayatri Nagar, Road No.14, Boduppall, R.R District-500039, Telangana.

Name: Name of Proxy:.....

Sign:..... Sign:.....

Note: 1. Only Members of the Company or their proxies will be allowed to attend the Meeting ON PRODUCTION OF ATTENDANCE SLIP duly completed and signed. 2. Please fill this admission slip and hand it over at the entrance of the hall duly signed. 3. Members are requested to bring their copies of Annual Report with them. 4. Members who hold shares in dematerialised form are requested to bring their Client ID and DP ID numbers for easy identification of attendance at the Meeting.

PROXY FORM

30th ANNUAL GENERAL MEETING on 29th SEPTEMBER, 2016

Regd. Folio No.:.....No. of Shares:DP ID No.:.....Client ID No:....

I/We.....of.....in the District ofbeing a Member(s) of the above Company hereby appoint.....resident ofin the District ofas my/our Proxy to attend and to vote for me/us on my/our behalf at the 30th Annual General Meeting of the Company to be held on the 29th September, 2016 at 11.00 A.M. at 9-109/9, Plot No.112, Gayatri Nagar, Road No.14, Boduppall, R.R District - 500039, Telangana. and at any adjournment thereof.

Signed this..... day ofTwo Thousand and Sixteen.

I hereby record my presence at the 30th ANNUAL GENERAL MEETING of the Members of the Company held on 29th September, 2016 at 11.00 A.M at 9-109/9, Plot No.112, Gayatri Nagar, Road No.14, Boduppall, R.R District - 500039, Telangana..

Name: Name of Proxy:.....

Sign:..... Sign:.....

Note: 1. This Proxy Form duly completed should be deposited at the Registered Office of the Company not less than 48 (Forty Eight) hours before the time fixed for holding the meeting. 2. Only Members of the Company or their proxies will be allowed to attend the Meeting ON PRODUCTION OF ATTENDANCE SLIP duly completed and signed. 3. Please fill this admission slip and hand it over at the entrance of the hall duly signed. 4. Members are requested to bring their copies of Annual Report with them. 5. Members who hold shares in dematerialised form are requested to bring their Client ID and DP ID numbers for easy identification of attendance at the Meeting.

POLLING PAPER

[Pursuant to Section 109 (5) of the Companies Act, 2013 and Rule 21 (1) (C) of the Companies (Management and Administration) Rules, 2014]

| | |
|---------------------|---|
| Name of the Company | : COMBAT DRUGS LIMITED 30th AGM: 29.09.16 |
| CIN | : CL23230TG1986PLC006781 |
| Registered Office | : 9-109/9, Plot No.112, Rd.No.14, Gayatri Nagar, Boduppal, R.R.Dist - 500039. TS. Telephone: 040-65523363 / 66200100 |
| Website | : www.combatdrugs.in |

BALLOT PAPER

| No. | Particulars | Details |
|-----|---|---------------|
| 1. | Name of the First Named Shareholder (In BLOCK letters) | |
| 2. | Postal address | |
| 3. | Registered Folio No./ *DP ID and Client ID No. (*Applicable to investors holding shares in dematerialized form) | |
| 4. | Class of Share | Equity Shares |

I hereby exercise my vote in respect of Ordinary/ Special Resolution/s enumerated below by recording my assent or dissent to the said resolution in the following manner:

| Sr. No. | ITEM NO. | No. of shares held by me | I assent to the resolution | I dissent from the resolution |
|---------|---|--------------------------|----------------------------|-------------------------------|
| 1. | <p>ORDINARY BUSINESS</p> <p>To receive, consider and adopt the Balance Sheet as at 31st March, 2016, the Profit and Loss Account for the year ended as on that date, Directors' Report and Auditors' Report thereon.</p> | | | |
| 2. | <p>To appoint a Director in place of Smt Vemuri Shilpa, as Independent Women Directorl who retires by rotation and being eligible offers herself for reappointment.</p> | | | |
| 3. | <p>To consider and if thought fit to pass the following resolution with or without modification(s) as Ordinary Resolution:</p> <p>“RESOLVED THAT M/s Anandam & Company, Chartered Accountants, be and are hereby appointed as Auditors of the Company to hold the office from the conclusion of this Annual General Meeting of the Company until the conclusion of next Annual General Meeting of the Company at a remuneration to be fixed by the Board of Directors in consultation with the Auditors.”</p> | | | |
| 4. | <p>SPECIAL BUSINESS</p> <p>APPOINTMENT OF INDEPENDENT DIRECTOR</p> <p>To consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution :</p> | | | |

| Sr. No. | ITEM NO. | No. of shares held by me | I assent to the resolution | I dissent from the resolution |
|---------|---|--------------------------|----------------------------|-------------------------------|
| | <p>“ RESOLVED THAT Mr. Bhupendralal Waghray, who was appointed as an Independent Director of the Company and who holds office up to the date of this Annual General Meeting and in respect of whom a notice has been received from a member of the Company in terms of Section 161 of the Companies Act, 2013, be and is hereby appointed as a Director of the Company liable to retire by rotation.”</p> | | | |

PRINTED MATTER

BOOK POST

If Undelivered please return to:

COMBAT DRUGS LIMITED

Regd Office: 9-109/9, Plot No. 112,
Road No. 14, Gayatri Nagar, Boduppall,
R.R. Dist. - 500 039. Telangana, India.
Phone: 040-65523363